Tranexamic acid
The specific mechanism of action of this competitive inhibitor of plasminogen in melasma remains unknown; it is believed to decrease melanogenesis in epidermal melanocytes and produce a downregulation of endothelin 1.[56]Kim SJ, Park JY, Shibata T, et al. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016 Jul;41(5):480-5.
http://www.ncbi.nlm.nih.gov/pubmed/27135282?tool=bestpractice.com
In one meta-analysis, tranexamic acid showed positive results as a single agent or in combination therapy for melasma.[57]Kim HJ, Moon SH, Cho SH, et al. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017 Jul 6;97(7):776-81.
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2668
http://www.ncbi.nlm.nih.gov/pubmed/28374042?tool=bestpractice.com
The results are more notable after 3 months of treatment; shorter treatments are more likely to lead to relapse.[57]Kim HJ, Moon SH, Cho SH, et al. Efficacy and safety of tranexamic acid in melasma: a meta-analysis and systematic review. Acta Derm Venereol. 2017 Jul 6;97(7):776-81.
https://www.medicaljournals.se/acta/content/html/10.2340/00015555-2668
http://www.ncbi.nlm.nih.gov/pubmed/28374042?tool=bestpractice.com
The most frequent adverse events observed with oral tranexamic acid are oligomenorrhea and gastrointestinal discomfort; other potential adverse events include thromboembolic events such as deep vein thrombosis, myocardial infarction, and pulmonary embolism, which are more likely to occur with higher doses than those used for melasma.[58]Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies. Dermatol Ther. 2017 May;30(3).
http://www.ncbi.nlm.nih.gov/pubmed/28133910?tool=bestpractice.com
[59]Sharma R, Mahajan VK, Mehta KS, et al. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol. 2017 Oct;42(7):728-34.
http://www.ncbi.nlm.nih.gov/pubmed/28649780?tool=bestpractice.com
Additional data suggest that intradermal tranexamic acid (including microinjection and microneedling) is equally as effective as oral administration and may have fewer side effects.[59]Sharma R, Mahajan VK, Mehta KS, et al. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol. 2017 Oct;42(7):728-34.
http://www.ncbi.nlm.nih.gov/pubmed/28649780?tool=bestpractice.com
Topical tranexamic acid has been studied at different concentrations. It is usually well tolerated and no severe side effects have been reported.[58]Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: a comprehensive review of clinical studies. Dermatol Ther. 2017 May;30(3).
http://www.ncbi.nlm.nih.gov/pubmed/28133910?tool=bestpractice.com
When comparing topical tranexamic acid with hydroquinone, no significant difference in Melasma Area and Severity Index (MASI) score was found; however, those treated with topical tranexamic acid had higher satisfaction with their treatment and fewer skin-related adverse events compared with those receiving hydroquinone.[60]Atefi N, Dalvand B, Ghassemi M, et al. Therapeutic effects of topical tranexamic acid in comparison with hydroquinone in treatment of women with melasma. Dermatol Ther (Heidelb). 2017 Sep;7(3):417-24.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574746
http://www.ncbi.nlm.nih.gov/pubmed/28748406?tool=bestpractice.com
One 2019 systematic review of randomized controlled trials gave a strong recommendation for tranexamic acid as a treatment for melasma.[29]Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: a systematic review of randomized controlled trials. J Drugs Dermatol. 2019 Nov 1;18(11):S1545961619P1156X.
https://jddonline.com/articles/topical-treatments-for-melasma-a-systematic-review-of-randomized-controlled-trials-S1545961619P1156X
http://www.ncbi.nlm.nih.gov/pubmed/31741361?tool=bestpractice.com
Owing to the lack of controls in some studies, the efficacy and administration route (oral, topical, or transdermal) for melasma needs further study.
Cysteamine
Cysteamine is the decarboxylated derivative of the amino acid cysteine. At high concentrations, it can inhibit melanogenesis. There are two double-blind randomized controlled trials with melasma patients treated with 5% cysteamine or placebo daily for 4 months.[61]Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. J Dermatolog Treat. 2018 Mar;29(2):182-9.
https://www.doi.org/10.1080/09546634.2017.1351608
http://www.ncbi.nlm.nih.gov/pubmed/28678558?tool=bestpractice.com
[62]Mansouri P, Farshi S, Hashemi Z, et al. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double-blind placebo-controlled trial. Br J Dermatol. 2015 Jul;173(1):209-17.
https://www.doi.org/10.1111/bjd.13424
http://www.ncbi.nlm.nih.gov/pubmed/25251767?tool=bestpractice.com
In both studies, cysteamine significantly reduced MASI scores compared to placebo. Cysteamine was well tolerated and the reported side effects were dryness, burning sensation, itching, redness, and irritation. One 2019 systematic review of randomized controlled trials gave a strong recommendation for cysteamine as a treatment for melasma.[29]Austin E, Nguyen JK, Jagdeo J. Topical treatments for melasma: a systematic review of randomized controlled trials. J Drugs Dermatol. 2019 Nov 1;18(11):S1545961619P1156X.
https://jddonline.com/articles/topical-treatments-for-melasma-a-systematic-review-of-randomized-controlled-trials-S1545961619P1156X
http://www.ncbi.nlm.nih.gov/pubmed/31741361?tool=bestpractice.com
Dioic acid
One small, open-label study comparing dioic acid versus hydroquinone (2%) in the treatment of melasma found both agents to be equally effective. Combination therapy was not found to be better than either treatment alone. However, less irritation was reported with dioic acid than with hydroquinone.[63]Tirado-Sanchez A, Santamaría-Roman A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol. 2009 Aug;48(8):893-5.
http://www.ncbi.nlm.nih.gov/pubmed/19659872?tool=bestpractice.com
Rucinol (4-n-butylresorcinol)
A resorcinol derivative that inhibits the activity of tyrosinase and tyrosinase-related protein-1 (TRP-1). It inhibits melanin production in a similar degree to hydroquinone and is more effective than arbutin or kojic acid. Efficacy in melasma has been reported to be between 70% and 80%.[64]Khemis A, Kaiafa A, Queille-Roussel C, et al. Evaluation of efficacy and safety of rucinol serum in patients with melasma: a randomized controlled trial. Br J Dermatol. 2007 May;156(5):997-1004.
http://www.ncbi.nlm.nih.gov/pubmed/17388924?tool=bestpractice.com
One study reported that the 0.1% cream has a fast onset of effect compared with other vehicles, decreasing the melanin index significantly after 4 weeks and 8 weeks.[65]Huh SY, Shin JW, Na JI, et al. The efficacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. Ann Dermatol. 2010 Feb;22(1):21-5.
http://www.ncbi.nlm.nih.gov/pubmed/20548876?tool=bestpractice.com
Procyanidin plus vitamins A, C, and E
Procyanidin is a condensed flavonoid and an active component of the bark extract of the French maritime pine (Pinus pinaster ssp. atlantica), which has anti-inflammatory and antioxidant properties. The overall efficacy in improving the MASI score and decreasing the pigment intensity is 80%.[66]Ni Z, Mu Y, Gulati O. Treatment of melasma with Pycnogenol. Phytother Res. 2002 Sep;16(6):567-71.
http://www.ncbi.nlm.nih.gov/pubmed/12237816?tool=bestpractice.com
[67]Handog EB, Galang DA, de Leon-Godinez MA, et al. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009 Aug;48(8):896-901.
http://www.ncbi.nlm.nih.gov/pubmed/19659873?tool=bestpractice.com
Microphthalmia-associated transcription factor (MITF)-siRNA
MITF regulates melanogenesis and is also involved in melanocyte development, function, and survival. MITF-siRNA significantly decreases the levels of tyrosinase, melanocortin-1 receptor (MC1R), and TRP-1, which suppresses melanin levels. In a small sample size, MITF-siRNA cream resulted in a good or excellent response in 90% of patients.[68]Yi X, Zhao G, Zhang H, et al. MITF-siRNA formulation is a safe and effective therapy for human melasma. Mol Ther. 2011 Feb;19(2):362-71.
http://www.ncbi.nlm.nih.gov/pubmed/21119619?tool=bestpractice.com
Amino fruit acid (AFA) peels
AFAs are carboxylated amino acids that act as an antioxidant, antiaging agent and have a significant antiphotopigmentation effect. In a small comparative study, AFA peels showed good efficacy. When compared with glycolic acid peels, AFA peels have fewer adverse effects and are better tolerated.[1]Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012 Jul;38(7 Pt 1):971-84.
http://www.ncbi.nlm.nih.gov/pubmed/22583339?tool=bestpractice.com
[69]Ilknur T, Biçak MU, Demirtaşoğlu M, et al. Glycolic acid peels versus amino fruit acid peels in the treatment of melasma. Dermatol Surg. 2010 Apr;36(4):490-5
http://www.ncbi.nlm.nih.gov/pubmed/20187899?tool=bestpractice.com
Ellagic acid
Ellagic acid is a natural antioxidant that can be found in different fruits and plants. It acts as a substrate for tyrosinase and it may have effects on the melanogenesis pathway. Twice-daily application has shown a decrease in the amount of melanin.[1]Ball Arefiev KL, Hantash BM. Advances in the treatment of melasma: a review of the recent literature. Dermatol Surg. 2012 Jul;38(7 Pt 1):971-84.
http://www.ncbi.nlm.nih.gov/pubmed/22583339?tool=bestpractice.com